4% more people given the PCSK9 inhibitor evolocumab (Repatha) to lower cholesterol levels died during an average follow-up of 2.2 years than those given a placebo according to the FOURIER trial.

444 people (out of 13,784) given evolocumab died compared to 426 people (out of 13,780) given a placebo.

So they want me to take a drug that you have to inject that costs $14,000 per year that increases my chance of dying?

No, thank you.